Immunovaccine to Present at Three Conferences in June
HALIFAX, NOVA SCOTIA -- (Marketwire) -- 06/13/12 -- Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE: IMV), a clinical stage vaccine company, today announced that John Trizzino, Chief Executive Officer, and Marc Mansour, Ph.D., Chief Science Officer, will participate in three upcoming conferences during the month of June. Details regarding these events are as follows:
2012 BIO International Convention
The Biotechnology Industry Organization (BIO) International Convention will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston.
-- Corporate Presentation Delivered by Mr. Trizzino Monday, June 18, 2012, 1:00 - 1:15 p.m. ET Room 105 (Bruins Room) -- "Therapeutic Cancer Vaccines: Renewed Optimism for the Product Pipeline" Panel participation by Dr. Mansour Track: Innovations in Vaccines Monday, June 18, 2012, 3:45 - 5:00 p.m. ET Room 208 -- "Montgomery County, Maryland - Press Conference and Entrepreneur Panel" Panel participation by Mr. Trizzino Tuesday, June 19, 2012, 3:00 - 4:30 p.m. ET Maryland Pavilion -- BIO Business Forum One-on-One Partnering Immunovaccine will participate in meetings with current and potential partners to discuss the Company's novel DepoVax™ adjuvanting delivery platform and ongoing development programs. If you are interested in scheduling a meeting with Immunovaccine at the BIO convention, please contact the Company directly or through the BIO One-on-One Partnering System.
Bloom Burton & Co. Healthcare Investor Conference
The inaugural Bloom Burton & Co. Healthcare Investor Conference will take place June 21, 2012 at the Toronto Board of Trade in Toronto.
-- Corporate Presentation Delivered by Mr. Trizzino Thursday, June 21, 2012, 3:00 - 3:30 p.m. ET (Ridout Room) Followed by Q&A breakout session, 3:30 - 4:00 p.m. ET (MacDonald Room)
Cancer Vaccines & Active Immunotherapeutics
The Cancer Vaccines & Active Immunotherapeutics 3rd Annual Summit will take place June 26-28, 2012 at the Sheraton Boston Hotel in Boston.
-- "Clinical Development of DPX-Survivac, a Multi-Cancer Vaccine Targeting the Broadly Expressed Tumor Associated Antigen Survivin" Presentation delivered by Dr. Mansour Wednesday, June 27, 2012, 3:00 p.m. ET -- "How Can We Change Our Early-Stage Study Design for Cancer Immunotherapies?" Panel participation by Dr. Marc Mansour Wednesday, June 27, 2012, 4:30 p.m. ET
Immunovaccine Inc. applies its novel vaccine delivery platform to the development of vaccines for cancer therapy and infectious diseases. The company's DepoVax™ platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses. Immunovaccine has advanced its platform technology and proprietary cancer vaccine into Phase I human clinical trials and has demonstrated both safety and immunogenicity potential. The Company is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based vaccines through multiple development collaborations. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has several key partnerships in the animal health sector including an agreement with Pfizer Animal Health, which has licensed the Company's delivery technology platform to develop vaccines for livestock. Connect at www.imvaccine.com.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Immunovaccine Inc. Kimberly Stephens (902) 492-1819 firstname.lastname@example.org www.imvaccine.com Vida Communication - Media Tim Brons (415) 675-7402 email@example.com Vida Communication - Investors - US Stephanie Diaz (415) 675-7401 firstname.lastname@example.org Capital Ideas Investor Relations - Investors - Canada Nadine Desruisseaux (647) 202-5292 nadine@capitalideasIR.com
Source: Immunovaccine Inc.
Released June 13, 2012